Gastrin (GAST) is a major gastrointestinal peptide hormone that plays a critical role in gastric acid secretion, mucosal growth, and oncogenic signaling pathways. Primarily synthesized by G-cells in the gastric antrum, gastrin operates through the Cholecystokinin B Receptor (CCKBR/CCK2R). Aberrant gastrin signaling is heavily implicated in hypergastrinemia, Zollinger-Ellison syndrome, and the progression of gastrointestinal malignancies, including gastric, pancreatic, and colorectal cancers. Targeting the gastrin-CCKBR axis via neutralizing monoclonal antibodies, peptide-drug conjugates (PDCs), and receptor antagonists represents a highly promising therapeutic frontier in oncology and gastroenterology.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Gastrin (GAST) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Gastrin (GAST) Recombinant Protein High purity (>95%), Endotoxin Controlled (<1.0 EU/μg). HEK293 expressed for native post-translational modifications. Sequence Verified. |
View GAST Products |
| Gene Delivery | Gastrin (GAST) Lentivirus Premade Particles Full-length human GAST ORF for stable cell line generation and expression validation. |
View GAST Products |
| Benchmark Ab | Anti-Gastrin (GAST) Recombinant Antibody Sequence-derived clinical benchmark antibody for positive control and assay validation. |
View GAST Products |
| Validator | Gastrin (GAST) siRNA Set Target-specific gene knockdown validation to confirm target specificity in cell-based assays. |
View GAST Products |
| Related Target A | CCKBR (Cholecystokinin B Receptor) The primary G-protein coupled receptor (GPCR) mediating gastrin signaling; critical for functional binding assays. |
View CCKBR Products |
| Related Target B | CCKAR (Cholecystokinin A Receptor) Homologous receptor used for counter-screening to verify therapeutic selectivity and avoid off-target effects. |
View CCKAR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Short peptide sequence (G-17/G-34) limits ELISA coating efficiency | HEK293-expressed GAST-Fc fusion proteins provide optimal steric availability and robust plate-coating stability. |
| High homology with Cholecystokinin (CCK) causing cross-reactivity | Sequence-verified antigens and dedicated CCKBR/CCKAR receptor panels enable strict selectivity profiling. |
| Lack of reliable positive control references | Recombinant biosimilar antibodies derived from clinical-grade sequences ensure assay reproducibility. |
| Target validation false positives in complex tumor microenvironments | Sequence-verified siRNA pools enable precise target knockdown to validate therapeutic specificity. |
Live Gastrin (GAST) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding Gastrin (GAST) is experiencing a resurgence. While early clinical efforts focused on therapeutic vaccines (such as G17DT/Gastrimmune) to elicit neutralizing antibodies against gastrin-17 in pancreatic and gastric cancers, modern drug discovery has expanded into targeted Peptide-Drug Conjugates (PDCs) and highly selective small molecule antagonists targeting the CCKBR receptor. As the role of the gastrin-CCKBR autocrine/paracrine loop in driving chemoresistance and epithelial-mesenchymal transition (EMT) becomes clearer, the next wave of R&D is heavily focused on combination regimens with immune checkpoint inhibitors and targeted cytotoxic payloads.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAbs / Vaccines | Academic Institutes, Biotech Spin-offs | Gastric Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Neutralization Assay (Requires high-purity, native-conformation GAST antigens) |
| Peptide-Drug Conjugates (PDCs) | Radiopharmaceutical & Oncology Developers | CCKBR-positive Advanced Solid Tumors | Binding & Internalization Validation (Requires CCKBR-expressing stable cell lines) |
| Small Molecule Antagonists | Trio Medicines (Netazepide), Pharmaceutical Innovators | Gastric Neuroendocrine Tumors (gNETs), Barrett's Esophagus | Selectivity Screening (Requires CCKBR vs. CCKAR comparative assay panels) |